Investigator sponsor of hcw biologics' phase 1 clinical trial presented human data readout and anti-cancer mechanism of action of hcw9218 at 38th sitc annual meeting

Showed hcw9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors results in ovarian cancer patients outpace other indications, with 66% stable disease miramar, fla., nov. 08, 2023 (globe newswire) -- hcw biologics inc.  (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing phase 1 clinical trial sponsored by the university of minnesota to evaluate hcw9218, the lead drug candidate of hcw biologics, in patients with solid tumors who failed at least two prior lines of therapy.
HCWB Ratings Summary
HCWB Quant Ranking